



TECH CENTER 1600/2900

OCT 09 2002

RECEIVED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO
						X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

MA	AA	Chen et al; (1998); "Green tea epigallocatechin gallate shows a pronounced growth inhibitory effect on cancerous cells but not on their normal counterparts"; Vol. 129; pp. 173-179
	AB	DeWitt; (1999); "Cox-2-selective inhibitors: the new super aspirins; Vol. 55, 4, pp. 625-631
	AC	Kim et al.; (1998); "Transcriptional Regulation of cyclooxygenase-2 in mouse skin Carcinoma cells"; Vol. 273, 42, pp. 27686-27694
	AD	Liang et al.; (1999); "Suppression of extracellular signals and cell proliferation by the black tea polyphenol, theaflavin-3,3' -digallate"; Vol 20, 4, pp. 733-736
	AE	Rogers et al.; (1998); "Black tea and mammary gland carcinogenesis by 7,12-Dimethylbenz [a]anthracene in Rats Fed Control or High Fat Diets"; Vol 19, 7, pp. 1269-1273
	AF	Subbaramaiah et al.; (1999); "Inhibition of Cyclooxygenase-2 Gene Expression by p53"; Vol. 274, 16, pp. 10911-10915
	AG	Weisburger et al.; (1998); "Effect of Black Tea on Azoxymethane-Induced Colon Cancer", Vol. 19, 1, pp. 229-232
	AH	Weisburger et al.; (1997); "Tea, or Tea and Milk, Inhibit Mammary Gland and Colon Carcinogenesis in Rats"; Vol. 114, pp.323-327
	AI	Vane et al.; (1998); "Cyclooxygenases 1 and 2"; Vol 38, pp.97-120
	AJ	Xu et al.; (1999); "Suppression of Inducible Cyclooxygenase 2 Gene Transcription by Aspirin and Sodium Salicylate"; Vol 96, pp. 5292-5297
↓	AK	Yang et al.; (1997); "Black Tea Constituents, Theaflavins, Inhibit 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in A/J Mice"; Vol 18, 12, pp.2361-2365

EXAMINER

DATE CONSIDERED

3/21/2003

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.